Cardiovascular comorbidities in atopic dermatitis: Potential implications for the use of Janus kinase inhibitors
To the Editor: The Food and Drug Administration recently approved the use of 2 oral Janus kinase (JAK) inhibitors —abrocitinib and upadacitinib—for patients with moderate-to-severe atopic dermatitis (AD) not adequately controlled with systemic therapies, including biologics, or when the use of such treatments is inadvisable.1,2 In September 2021, the Food and Drug Administration issued a boxed warning for a ll JAK inhibitors regarding the increased risk of serious infections, heart attack, stroke, cancer, blood clots, and death.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: J. Mark Jackson, Amanda Althoff, Lawrence Rasouliyan, Stacey Long, Carla L. Zema Tags: Research letter Source Type: research
More News: Academies | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Dermatitis | Dermatology | Food and Drug Administration (FDA) | Heart | Heart Attack | Legislation | Oral Cancer | Skin | Stroke | Warnings